Stanley T. Crooke Sells 22,000 Shares of Ionis Pharmaceuticals Inc. (IONS) Stock
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) Chairman Stanley T. Crooke sold 22,000 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Tuesday, September 27th. The shares were sold at an average price of $36.02, for a total transaction of $792,440.00. Following the completion of the transaction, the chairman now directly owns 45,029 shares in the company, valued at approximately $1,621,944.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Ionis Pharmaceuticals Inc. (NASDAQ:IONS) opened at 35.57 on Friday. Ionis Pharmaceuticals Inc. has a 1-year low of $19.59 and a 1-year high of $65.34. The firm’s market cap is $4.30 billion. The firm’s 50-day moving average is $32.53 and its 200-day moving average is $32.43.
Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. Ionis Pharmaceuticals had a negative return on equity of 126.88% and a negative net margin of 128.94%. The company had revenue of $38.50 million for the quarter, compared to analysts’ expectations of $38.52 million. The business’s quarterly revenue was down 68.0% on a year-over-year basis. On average, analysts anticipate that Ionis Pharmaceuticals Inc. will post ($1.11) EPS for the current fiscal year.
Several large investors have recently made changes to their positions in IONS. Parametric Risk Advisors LLC bought a new stake in shares of Ionis Pharmaceuticals during the first quarter worth about $106,000. Rockefeller Financial Services Inc. bought a new stake in shares of Ionis Pharmaceuticals during the second quarter worth about $114,000. Opera Trading Capital boosted its stake in shares of Ionis Pharmaceuticals by 150.0% in the first quarter. Opera Trading Capital now owns 2,892 shares of the company’s stock worth $117,000 after buying an additional 1,735 shares in the last quarter. US Bancorp DE boosted its stake in shares of Ionis Pharmaceuticals by 37.8% in the second quarter. US Bancorp DE now owns 5,952 shares of the company’s stock worth $139,000 after buying an additional 1,634 shares in the last quarter. Finally, GAM Holding AG boosted its stake in shares of Ionis Pharmaceuticals by 118.5% in the second quarter. GAM Holding AG now owns 7,727 shares of the company’s stock worth $180,000 after buying an additional 4,191 shares in the last quarter. Institutional investors own 89.58% of the company’s stock.
IONS has been the topic of a number of recent analyst reports. Cowen and Company reissued a “buy” rating on shares of Ionis Pharmaceuticals in a research report on Wednesday, August 3rd. Piper Jaffray Cos. reissued an “overweight” rating and issued a $46.00 price target on shares of Ionis Pharmaceuticals in a research report on Monday. Jefferies Group reissued an “underperform” rating and issued a $12.00 price target on shares of Ionis Pharmaceuticals in a research report on Friday, July 15th. Leerink Swann reissued a “market perform” rating and issued a $36.00 price target (up previously from $26.00) on shares of Ionis Pharmaceuticals in a research report on Tuesday, August 2nd. Finally, Needham & Company LLC lifted their price target on shares of Ionis Pharmaceuticals from $55.00 to $64.00 and gave the company a “buy” rating in a research report on Monday, August 1st. Two research analysts have rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Ionis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $41.82.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc, formerly Isis Pharmaceuticals, Inc, is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform.
Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.